Cara Therapeutics announces Phase II data for peripheral analgesic in acute post-operative pain
Feb8
9 February 2010 – US biotechnology company Cara Therapeutics Inc reported yesterday encouraging data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845.The 46-patient, Phase II, multi-centre, double-blind, placebo-controlled study was conducted at eight hospitals in the US and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted [...]
